Corpus overview


MeSH Disease

Human Phenotype

Pneumonia (1279)

Fever (758)

Cough (617)

Hypertension (438)

Anxiety (416)


age categories (3405)

Transmission (3073)

gender (1563)

fomite (1290)

contact tracing (1125)

    displaying 15851 - 15860 records in total 16184
    records per page

    Asians Do Not Exhibit Elevated Expression or Unique Genetic Polymorphisms for ACE2, the Cell-Entry Receptor of SARS-CoV-2

    Authors: Ying Chen; Kejia Shan; Wenfeng Qian

    id:10.20944/preprints202002.0258.v2 Date: 2020-02-25 Source:

    The recurrent coronavirus outbreaks in China ( SARS-CoV MESHD and its relative, SARS-CoV-2) have raised speculations that perhaps Asians are somehow more susceptible to these coronaviruses. Here, we test this possibility based on an analysis of the lung-specific expression of ACE2, which encodes the known cell-entry receptor of both SARS-CoV and SARS-CoV-2 MESHD. We show that ACE2 expression is not affected during tumorigenesis, supporting that the abundant transcriptomes in cancer MESHD genomic studies can be informatively used to study ACE2 expression among diverse individuals without cancer MESHD. We find that ACE2 expression in the lung increases with age TRANS, but is not associated with sex. Further, Asians do not differ from other populations for ACE2 expression and do not harbor unique genetic polymorphisms in the ACE2 locus. Thus, beyond illustrating an innovative method for assessing the potential impacts of demographic factors for non-cancer diseases MESHD from large-scale cancer sample datasets, our statistically robust findings emphasize that individuals of all races require the same level of personal protection against SARS-CoV-2.

    Epidemiological and clinical characteristics of SARS-CoV-2 and SARS-CoV MESHD: a system review

    Authors: mao yaqian; Wei Lin; Junping Wen; Gang Chen

    doi:10.1101/2020.02.20.20025601 Date: 2020-02-25 Source: medRxiv

    Importance: In 2002-2003, a severe pulmonary infectious disease MESHD occurred in Guangdong, China. The disease was caused by SARS-CoV MESHD, 17 years apart, also happen in China, and SARS-CoV-2, this epidemic has posed a significant hazard to people health both China and the whole world. Objective: Summarized the latest epidemiological changes, clinical manifestations, auxiliary examination and pathological characteristics of COVID-19. Evidence Review: PubMed database were searched from 2019 to 2020 using the index terms novel coronavirus or COVID-19 or 2019-nCoV or SARS-CoV-2 and synonyms. Articles that reported clinical characteristics, laboratory results, imageological diagnosis and pathologic condition were included and were retrospectively reviewed for these cases. This paper adopts the method of descriptive statistics. Results: 34 COVID-19-related articles were eligible for this systematic review;Four of the articles were related to pathology. We found that Fever HP Fever MESHD (86.0%), cough HP (63.9%) and Malaise/Fatigue MESHD Fatigue HP (34.7%) were the most common symptoms in COVID-19. But in general, the clinical symptoms and signs of COVID-19 were not obvious. Compared with SARS, COVID-19 was transmitted in a more diverse way. The mortality rates of COVID-19 were 2.5%, and the overall infection rate of healthcare worker of COVID-19 was 3.9%. We also found that the pathological features of COVID-19 have greatly similar with SARS, which manifested as ARDS. But the latest pathological examination of COVID-19 revealed the obvious mucinous secretions in the lungs. Interpretation: The clinical and pathological characteristics of SARS and COVID-19 in China are very similar, but also difference. The latest finds of pathological examination on COVID-19 may upend existing treatment schemes, so the early recognition of disease by healthcare worker is very important.

    Predicting the Cumulative Number of Cases for the COVID-19 Epidemic in China From Early Data

    Authors: Zhihua Liu; Pierre Magal; Ousmane Seydi; Glenn Webb

    id:10.20944/preprints202002.0365.v1 Date: 2020-02-25 Source:

    We model the COVID-19 coronavirus epidemic in China. We use early reported case data to predict the cumulative number of reported cases to a final size. The key features of our model are the timing of implementation of major public policies restricting social movement, the identification and isolation of unreported cases, and the impact of asymptomatic TRANS infectious cases.

    SARS-CoV-2 transmission TRANS in cancer MESHD patients of a tertiary hospital in Wuhan

    Authors: Jing Yu; Wen Ouyang; Melvin L.K. Chua; Conghua Xie

    doi:10.1101/2020.02.22.20025320 Date: 2020-02-25 Source: medRxiv

    In December 2019, an outbreak of atypical pneumonia HP pneumonia MESHD known as 2019 novel coronavirus disease MESHD (COVID-19) occurred in Wuhan, China. This new type of pneumonia HP pneumonia MESHD is characterized by rapid human-to-human transmission TRANS. Among the different disease types, cancer MESHD patients are often recalled SERO to the hospital for treatment and disease surveillance, and the majority of cancer MESHD treatments such as chemotherapy and radiotherapy are immunosuppressive. This prompts us to consider if cancer MESHD patients were at an elevated risk of SARS-CoV-2 infection MESHD. A total of 1,524 cancer MESHD patients who were managed at our tertiary cancer MESHD institution-Zhongnan hospital of Wuhan University were reviewed during the period of Dec 30, 2019 to Feb 17, 2020. It was found that cancer MESHD patients had an estimated 2-fold increased risk of COVID-19 than the general population. We identified twelve patients who were infected with SARS-CoV-2, with two recorded deaths (16.7%), albeit one patient passed away from a COVID-19 unrelated cause. Interestingly, only five of these patients were ongoing treatment at the time of contracting the virus, suggesting that hospital visitation was the likely factor contributing to the elevated incidence in cancer MESHD patients. Moreover, we also observed that the incidence of severe COVID-19 was not higher than in the general population. Consequently, for cancer MESHD patients who require treatment, proper isolation protocols must be in place to mitigate the risk of SARS-CoV-2 infection MESHD.

    Generation of antibodies SERO against COVID-19 virus for development of diagnostic tools

    Authors: Maohua Li; Ronghua Jin; Ya Peng; Cuiyan Wang; Wenlin Ren; Fudong Lv; Sitao Gong; Feng Fang; Qianyun Wang; Jianli Li; Tong Shen; Hunter Sun; Lei Zhou; Yali Cui; Hao Song; Le Sun

    doi:10.1101/2020.02.20.20025999 Date: 2020-02-25 Source: medRxiv

    The COVID-19 China coronavirus started in Dec 2019 was challenged by the lack of accurate serological diagnostic tool for this deadly disease to quickly identify and isolate the infected MESHD patients. The generation of COVID-19-specific antibodies SERO is essential for such tasks. Here we report that polyclonal and monoclonal antibodies SERO were generated by immunizing animals with synthetic peptides corresponding to different areas of Nucleoprotein (N) of COVID-19. The specificities of the COVID-19 antibodies SERO were assessed by Western Blot analysis against NPs from COVID-19, MERS and SARS. Antibodies SERO were used for immunohistochemistry staining of the tissue sections from COVID-19 infected patient, as a potential diagnostic tool. A Sandwich ELISA SERO kit was quickly assembled for quantitation of the virus/NP of COVID-19 concentrations in the vaccine preparations. Development of POCT is also aggressively undergoing.

    The experience of high flow nasal cannula in hospitalized patients with 2019 novel coronavirus–infected pneumonia MESHD pneumonia HP in Chongqing, China

    Authors: Ke Wang; Wei Zhao; Ji Li; Weiwei Shu; Jun Duan

    doi:10.21203/rs.2.24633/v1 Date: 2020-02-25 Source: ResearchSquare

    Background The outbreak of a novel coronavirus (2019-nCoV)– infected pneumonia MESHD pneumonia HP (NCIP) is currently ongoing in China. Most of the critically ill patients received high flow nasal cannula (HFNC). However, the experience of HFNC in this population is lacking. Methods We retrospectively collected the NCIP patients who received HFNC in two hospital of Chongqing, China from January 1st to February 18th, 2020. The clinical characteristics were collected. Patients who required upgrading to noninvasive ventilation (NIV) were defined as HFNC failure MESHD. Results We enrolled 17 patients in this study. Of them, 7 patients (41%) experienced HFNC failure MESHD (6 required upgrading to NIV, and one to NIV and further to intubation). The HFNC failure rate was 0% (0/6), 57% (4/7) and 75% (3/4) (p =0.03 between 3 groups) in patients with PaO2/FiO2 >200, 150-200, and <150 mmHg, respectively. In the successful patients, the respiratory rate, heart rate and PaO2/FiO2 significantly improved from initiation to termination of HFNC (27±3 vs. 21±2 breaths/min, p <0.01; 86±15 vs. 76±12 beats/min, p =0.03; and 213±49 vs. 299±125 mmHg, p =0.04, respectively). However, in the unsuccessful patients, the respiratory rate and PaO2/FiO2 significantly deteriorated (22±3 vs. 25±3 breaths/min, p =0.04; and 160±27 vs. 105±24 mmHg, p =0.01, respectively). When they upgraded to NIV, the PaO2/FiO2 improved after 1-2 h of NIV (105±24 vs. 202±111 mmHg, p =0.04). In the total cohort, only PaO2/FiO2 at baseline was lower in unsuccessful patients than that in successful ones (213±49 vs. 160±27 mmHg, p =0.02). Conclusions This study firstly provides the experience of how to use HFNC in patients with NCIP. Patients with lower PaO2/FiO2 were more likely to experience HFNC failure MESHD. Among the failure MESHD patients, most of them can avoid intubation when they were ungraded to NIV.

    Higher severity and mortality in male TRANS patients with COVID-19 independent of age TRANS and susceptibility

    Authors: Jian-Min Jin; Peng Bai; Wei He; Fei Wu; Xiao-Fang Liu; De-Min Han; Shi Liu; Jin-Kui Yang

    doi:10.1101/2020.02.23.20026864 Date: 2020-02-25 Source: medRxiv

    Importance: The recent outbreak of Novel Coronavirus ( SARS-CoV-2) Disease MESHD (COVID-19) has put the world on alert, that is reminiscent of the SARS outbreak seventeen years ago. Objective: We aim to compare the severity and mortality between male TRANS and female TRANS patients with both COVID-19 and SARS, to explore the most useful prognostic factors for individualized assessment. Design, Setting, and Participants: We extracted the data from a case series of 43 hospitalized patients we treated, a public data set of the first 37 cases died of COVID-19 in Wuhan city and 1019 survived patients from six cities in China. We also analyzed the data of 524 patients with SARS, including 139 deaths MESHD, from Beijing city in early 2003. Main Outcomes and Measures: Severity and mortality. Results: Older age TRANS and high number of comorbidities were associated with higher severity and mortality in patients with both COVID-19 and SARS. The percentages of older age TRANS ([≥]65 years) were much higher in the deceased group than in the survived group in patients with both COVID-19 (83.8 vs. 13.2, P<0.001) and SARS (37.4 vs. 4.9, P<0.001). In the case series, men tend to be more serious than women (P=0.035), although age TRANS was comparable between men and women. In the public data set, age TRANS was also comparable between men and women in the deceased group or the survived group in patients with COVID-19. Meanwhile, gender TRANS distribution was exactly symmetrical in the 1019 survivors of COVID-19. However, the percentage of male TRANS were higher in the deceased group than in the survived group (70.3 vs. 50.0, P=0.015). The gender TRANS role in mortality was also observed in SARS patients. Survival analysis showed that men (hazard ratio [95% CI] 1.47 [1.05-2.06, P= 0.025) had a significantly higher mortality rate than women in patients with SARS. Conclusions and Relevance: Older age TRANS and male TRANS gender TRANS are risk factors for worse outcome in patients with COVID. While men and women have the same susceptibility to both SARS-CoV-2 and SARS-CoV MESHD, men may be more prone to have higher severity and mortality independent of age TRANS and susceptibility.

    Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series

    Authors: Guo-Qing Qian; Nai-Bin Yang; Feng Ding; Ada Hoi Yan Ma; Zong-Yi Wang; Yue-Fei Shen; Chun-Wei Shi; Xiang Lian; Jin-Guo Chu; Lei Chen; Zhi-Yu Wang; Da-Wei Ren; Guo-Xiang Li; Xue-Qin Chen; Hua-Jiang Shen; Xiao-Min Chen

    doi:10.1101/2020.02.23.20026856 Date: 2020-02-25 Source: medRxiv

    Background Recent studies have focused initial clinical and Epidemiologic characteristics on the COVID-19, mainly revealing situation in Wuhan, Hubei. Aim To reveal more data on the epidemiologic and clinical characteristics of COVID-19 patients outside of Wuhan, in Zhejiang, China. Design Retrospective case series. Methods 88 cases of laboratory-confirmed and 3 cases of clinical-confirmed COVID-19 were admitted to five hospitals in Zhejiang province, China. Data were collected from 20 January 2020 to 11 February 2020. Results Of all 91 patients, 88 (96.70%) were laboratory-confirmed COVID-19 with throat swab samples that tested positive for SARS-Cov-2 while 3 (3.30%) were clinical-diagnosed COVID-19 cases. The median age TRANS of the patients was 50 (36.5-57) years, and female TRANS accounted for 59.34%. In this sample 40 (43.96%) patients had contracted the diseases from local cases, 31 (34.07%) patients had been to Wuhan/Hubei, 8 (8.79%) cases had contacted with people from Wuhan, 11 (12.09%) cases were confirmed TRANS aircraft transmission TRANS. In particular within the city of Ningbo, 60.52% cases can be traced TRANS back to an event held in a temple. The most common symptoms were fever HP fever MESHD (71.43%), cough HP (60.44%) and fatigue HP fatigue MESHD (43.96%). The median of incubation period TRANS was 6 (IQR, 3-8) days and the median time from first visit to a doctor to confirmed diagnosis was 1 (1-2) days. According to the Chest computed tomography scans, 67.03% cases had bilateral pneumonia MESHD pneumonia HP. Conclusions Social activity cluster, family cluster and travel TRANS by airplane were how COVID-19 patients get transmitted and could be rapidly diagnosed COVID-19 in Zhejiang.

    Temperature significant change COVID-19 Transmission TRANS in 429 cities

    Authors: Mao Wang; Aili Jiang; Lijuan Gong; Lina Luo; Wenbin Guo; Chuyi Li; Jing Zheng; Chaoyong Li; Bixing Yang; Jietong Zeng; Youping Chen; Ke Zheng; Hongyan Li

    doi:10.1101/2020.02.22.20025791 Date: 2020-02-25 Source: medRxiv

    Background There is no evidence supporting that temperature changes COVID-19 transmission TRANS. Methods We collected the cumulative number of confirmed cases TRANS of all cities and regions affected by COVID-19 in the world from January 20 to February 4, 2020, and calculated the daily means of the average, minimum and maximum temperatures in January. Then, restricted cubic spline function and generalized linear mixture model were used to analyze the relationships. Results There were in total 24,232 confirmed cases TRANS in China and 26 overseas countries. In total, 16,480 cases (68.01%) were from Hubei Province. The lgN rose as the average temperature went up to a peak of 8.72 and then slowly declined. The apexes of the minimum temperature and the maximum temperature were 6.70 and 12.42 respectively. The curves shared similar shapes. Under the circumstance of lower temperature, every 1 increase in average, minimum and maximum temperatures led to an increase of the cumulative number of cases by 0.83, 0.82 and 0.83 respectively. In the single-factor model of the higher-temperature group, every 1 increase in the minimum temperature led to a decrease of the cumulative number of cases by 0.86. Conclusion The study found that, to certain extent, temperature could significant change COVID-19 transmission TRANS, and there might be a best temperature for the viral transmission TRANS, which may partly explain why it first broke out in Wuhan. It is suggested that countries and regions with a lower temperature in the world adopt the strictest control measures to prevent future reversal.

    2019 Novel Coronavirus can be detected in urine, blood SERO, anal swabs and oropharyngeal swabs samples

    Authors: Liang Peng; Jing Liu; Wenxiong Xu; Qiumin Luo; Keji Deng; Bingliang Lin; Zhiliang Gao

    doi:10.1101/2020.02.21.20026179 Date: 2020-02-25 Source: medRxiv

    We tested samples collected from nine patients diagnosed with coronavirus disease MESHD 2019 (COVID-19). The virus was found in urine, blood SERO, anal swabs and oropharyngeal swabs. It is the first time for SARS-CoV-2 found in urine, though no urinary irritation was found.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.